DMRA Damora Therapeutics, Inc. Ordinary Shares

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

DMRA — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$1.3B
Employees
7
List Date
2020-10-29
CIK
0001800315
Next Earnings
2026-11-05
EPS Forecast
($0.52) (3 est.)
Headquarters
Waltham, MA
Homepage
https://www.damoratx.com

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'26Avg
Jan----
Feb----
Mar1.53%1.53%
Apr2.31%2.31%
May-1.89%-1.89%
Jun4.67%4.67%
Jul8.54%8.54%
Aug-1.33%-1.33%
Sep-24.38%-24.38%
Oct5.09%*5.09%
Nov----
Dec----
Total-9.21%-9.21%
* Only 1 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $20.22
SMA 50: $24.30
SMA 200: —
Current: $21.26
EMA 12: $20.58
EMA 26: $21.35
MACD: -0.7697 | Signal: 0.5173
BEARISH
ADX (14): 24.73
WEAK TREND
+DI: 23.96
−DI: 22.72

Momentum Oscillators

RSI (14): 48.99
NEUTRAL
Stoch %K: 74.51
Stoch %D: 76.04
Williams %R: -27.29

Volume & Volatility

BB Upper: $22.27
BB Lower: $18.17
NEUTRAL
OBV: 2,655,675
Vol SMA 20: 478,972
Vol ROC: 139.56%
ATR: $1.45
True Range: $0.70
HV 20: 59.6%
HV 30: 71.0%
HV 60: 63.6%

Data Summary

Data Points: 160
Last Updated:
Date Range: 2026-03-10T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary: BULLISH/BEARISH: NEUTRAL (6/10)

Key drivers:

  • Technical indicators suggest a range-bound market with a potential breakout to the upside
  • Recent news sentiment is neutral, but the company's announcement of inducement grants may have positive implications

Primary risks:

  • High volatility, with beta above 1.3 relative to the SPY
  • Lack of recent earnings data and options activity may indicate limited catalysts for price movement

Investment thesis: DMRA's shares are trading in a range-bound market, but the potential for a breakout to the upside is supported by technical indicators. The company's recent news sentiment has been neutral, with no significant events driving price movements.

Recent news sentiment impact: The neutral sentiment from the company's announcement of inducement grants may not have a significant impact on the stock's price movement in the short term.

Technical Analysis:

Trend Direction:

  • Short-term (1-4 weeks): NEUTRAL
  • Medium-term (1-3 months): UPTREND
  • Long-term (3-12 months): NEUTRAL

Support/Resistance Levels:

  • SMA 20: $30.02 (support)
  • SMA 50: $29.80 (support)
  • Upper Bollinger Band: $32.58 (resistance)

Momentum Signals:

  • RSI: 44.55 (neutral)
  • MACD: -0.26 / Signal: -0.23 / Histogram: -0.02 (bearish)
  • Bollinger Bands position: neutral

Volume Analysis:

  • Volume SMA 20: 310983.75
  • On-Balance Volume (OBV): 7561734.64
  • Volume Rate of Change: -87.50%

News & Sentiment Analysis:

Recent Headlines Summary: The company has announced inducement grants for employees, which may have positive implications but is neutral in terms of price movement.

Sentiment Assessment: Positive sentiment from the employee grant announcements, but overall sentiment remains neutral.

Catalyst Identification: No significant earnings dates or product launches scheduled in the near term.

Market Narrative: The news sentiment aligns with the technical signals, suggesting a range-bound market with potential for a breakout to the upside.

Risk & Volatility Assessment:

Beta Interpretation: High risk relative to the SPY, with beta above 1.3.

Volatility Regime: Current volatility is higher than historical levels, with IV Premium vs HV30 indicating an implied richer than realized volatility.

Options Market Signals: No options data available for analysis.

Downside Protection: Support levels include SMA 20 at $30.02 and SMA 50 at $29.80. Risk management considerations include setting stop-loss levels around the lower Bollinger Band at $27.45.

Market Context & Positioning:

Sector Performance: DMRA's sector performance is neutral relative to the overall market.

Institutional Activity: Volume patterns suggest institutional interest, with a volume rate of change of -87.50%.

Correlation Analysis: The stock moves relatively independently of the market, with an R-squared value indicating low correlation.

Relative Valuation: Position within trading range, with potential for a breakout to the upside or downside.

Key Levels & Action Items:

Critical Price Levels:

  • SMA 20 at $30.02 (support)
  • SMA 50 at $29.80 (support)
  • Upper Bollinger Band at $32.58 (resistance)

Breakout/Breakdown Levels: The lower Bollinger Band at $27.45 and the upper Bollinger Band at $32.58 are key levels to monitor.

Time-Sensitive Catalysts: No significant earnings dates or product launches scheduled in the near term.

Risk Management: Set stop-loss levels around the lower Bollinger Band at $27.45, and consider position sizing based on risk tolerance.

Generated

DMRA Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.3388
Alpha: -27.40%
Correlation: 0.2307
R-Squared: 5.3%
Stock Volatility: 77.0%
Market Volatility: 13.3%

Analysis Details

Benchmark: SPY
Data Points: 159
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

DMRA Institutional Ownership (13F)

Latest filings — 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

108 filers66,873,673 shares$1.74B value
# Filer Shares Value % of Total % of Float Period
1 FMR LLC Custodian 9,232,979 $240.15M 13.84% — 2026-06-30
2 Fairmount Funds Management LLC 8,713,000 $226.63M 13.06% — 2026-06-30
3 Avoro Capital Advisors LLC 3,783,000 $98.40M 5.67% — 2026-06-30
4 Venrock Adviser, LLC 3,603,595 $93.73M 5.40% — 2026-06-30
5 BlackRock, Inc. Custodian 3,162,068 $82.25M 4.74% — 2026-06-30
6 FCPM III SERVICES B.V. 2,441,000 $63.49M 3.66% — 2026-06-30
7 RA CAPITAL MANAGEMENT, L.P. 2,399,702 $62.42M 3.60% — 2026-06-30
8 Janus Henderson Group plc 2,362,696 $61.44M 3.54% — 2026-03-31
9 VIKING GLOBAL INVESTORS LP 2,311,082 $60.11M 3.46% — 2026-06-30
10 Jupiter Topco LLC 2,282,804 $59.28M 3.42% — 2026-06-30
11 Remedium Capital Partners, LLC 2,045,473 $53.20M 3.07% — 2026-06-30
12 Commodore Capital LP 1,939,000 $50.43M 2.91% — 2026-06-30
13 JPMorgan Chase & Co Custodian 2,058,933 $49.85M 2.87% — 2026-06-30
14 BRAIDWELL LP 1,620,377 $42.15M 2.43% — 2026-06-30
15 Bellevue Group AG 1,618,846 $42.11M 2.43% — 2026-06-30
16 State Street Corp 1,545,500 $40.20M 2.32% — 2026-06-30
17 a16z Capital Management, L.L.C. 1,236,157 $32.15M 1.85% — 2026-06-30
18 Balyasny Asset Management L.P. 1,229,127 $31.97M 1.84% — 2026-06-30
19 PERCEPTIVE ADVISORS LLC 1,223,000 $31.81M 1.83% — 2026-06-30
20 Wellington Management Group LLP Custodian 1,058,000 $27.52M 1.59% — 2026-06-30
21 Blackstone Inc. 1,002,971 $26.09M 1.50% — 2026-06-30
22 Cormorant Asset Management, LP 1,000,000 $26.01M 1.50% — 2026-06-30
23 Geode Capital Management, LLC Custodian 965,364 $25.11M 1.45% — 2026-06-30
24 Siren, L.L.C. 900,000 $23.41M 1.35% — 2026-06-30
25 UBS Group AG Custodian 840,292 $21.86M 1.26% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

DMRA Insider Trading (Form 4)

Latest: 2026-09-28
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-09-28 Jennifer Jarrett Director, President and CEO Buy (P) +12,500 $20.23 $252.9K EDGAR
2026-08-13 Andrew Cheng Director Grant (A) +30,350 opt — EDGAR
2026-07-07 Garrett Winslow General Counsel Mixed +435 $29.98 -$7.3K EDGAR
2026-04-01 Jennifer Jarrett See Remarks Award (A) +500,000 — EDGAR
2026-03-25 Michael Landsittel Director Grant (A) +37,313 opt — EDGAR
2026-03-25 Cameron Turtle Director Grant (A) +37,313 opt — EDGAR
2026-03-25 Julianne Bruno Director Grant (A) +37,313 opt — EDGAR
2026-03-25 Garrett Winslow General Counsel Grant (A) +250,000 opt — EDGAR
2026-03-25 Fairmount Healthcare Fund II L.P. Director Grant (A) +186,565 opt — EDGAR
2026-03-25 Christopher W. Cain Director Grant (A) +37,313 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

DMRA Insider Holdings

2 insiders · @ $21.26
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Jennifer Jarrett Director, President and CEO 512,500 $10.90M $252.9K 2 2026-09-28
2 Garrett Winslow General Counsel 2,534 $53.9K -$7.3K 2 2026-07-07
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

DMRA Board & Officers

As of SEC filings through Sep 28, 2026

Directors 11

Officers 5

10% owners 5

Changes in the last 10 years (68)
Aug 12, 2026Andrew Cheng became a director
May 1, 2026Brian Burkavage became SVP, Finance
Apr 28, 2026The company announced the departure of Lori Firmani as Interim CFO in an SEC filing
Mar 30, 2026Jennifer Jarrett became a director
Mar 30, 2026Jennifer Jarrett became President and Chief Executive Officer
Mar 25, 2026Fairmount Healthcare Fund II L.P. first listed as a director in an SEC filing
Mar 25, 2026Fairmount Healthcare Co-Invest V L.P. first listed as a director in an SEC filing
Mar 23, 2026Michael Landsittel became a director
Mar 23, 2026Cameron Turtle became a director
Mar 20, 2026The company announced the departure of Jayson Donald Alexander Dallas from the board in an SEC filing
Mar 20, 2026The company announced the departure of Carl Goldfischer from the board in an SEC filing
Mar 20, 2026The company announced the departure of Amit Munshi from the board in an SEC filing
Feb 6, 2026The company announced the departure of Hans T. Schambye as Chief Executive Officer in an SEC filing
Jan 5, 2026Sherwin Sattarzadeh became Chief Operating Officer
Jan 5, 2026L. Becker Hewes became Chief Medical Officer
Nov 10, 2025Tomas Kiselak became a 10% owner
Nov 10, 2025The company announced the departure of David Shapiro from the board in an SEC filing
Nov 10, 2025The company announced the departure of Anne Prener from the board in an SEC filing
Nov 10, 2025The company announced the departure of Amy B Wechsler from the board in an SEC filing
Nov 10, 2025Peter Evan Harwin became a director
Not reported recently (9)
  • Matthew Kronmiller · Last reported as EVP Strategy and CBO in an SEC filing dated Jan 7, 2025
  • Jonathan Freve · Last reported as Chief Financial Officer in an SEC filing dated Jan 5, 2024
  • Chau Quang Khuong · Last reported as a director in an SEC filing dated Jun 15, 2023
  • Anders Pedersen · Last reported as Chief Operating Officer in an SEC filing dated Jan 5, 2023
  • Bertil Lindmark · Last reported as Chief Medical Officer in an SEC filing dated Jan 5, 2023
  • Stephanie Oestreich · Last reported as Chief Business Officer in an SEC filing dated Jan 5, 2023
  • Novo Holdings A/S · Last reported as a 10% owner in an SEC filing dated Nov 4, 2020
  • Stephan Christgau · Last reported as a director in an SEC filing dated Nov 4, 2020
  • Soren Moller · Last reported as a director in an SEC filing dated Oct 28, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

DMRA Proposed Insider Sales (Form 144)

Latest: 2026-08-06
Last 30d: 0 filings  ·  Last 90d: 1 filing · $56K notice value · 1 unique filer

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Firmani Lori (1, $56K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-06 Firmani Lori Officer 1,800 $56.0K 2026-08-05 Maxim Group — EDGAR
2026-06-22 Firmani Lori Officer 7,615 $193.1K 2026-06-22 Maxim Group — EDGAR
2023-10-02 The Biotech Growth Trust PLC Shareholder 57,312 $41.3K 2023-10-02 Merrill Lynch, Pierce, Fenner & … — EDGAR
2023-10-02 OrbiMed Israel Partners II, L.P. Shareholder 244,527 $176.1K 2023-10-02 Merrill Lynch, Pierce, Fenner & … — EDGAR
2023-10-02 OrbiMed Genesis Master Fund, L.P. Shareholder 37,675 $27.1K 2023-10-02 Merrill Lynch, Pierce, Fenner & … — EDGAR
2023-10-02 OrbiMed Private Investments VII, LP Shareholder 585,274 $421.4K 2023-10-02 Merrill Lynch, Pierce, Fenner & … — EDGAR
2023-08-30 The Biotech Growth Trust PLC Shareholder 119,679 $69.4K 2023-08-30 Bank of America — EDGAR
2023-08-30 OrbiMed Israel Partners II, L.P. Shareholder 510,610 $296.2K 2023-08-30 Bank of America — EDGAR
2023-08-30 OrbiMed Genesis Master Fund, L.P. Shareholder 78,659 $45.6K 2023-08-30 Bank of America — EDGAR
2023-08-30 OrbiMed Private Investments VII, LP Shareholder 1,222,125 $708.8K 2023-08-30 Bank of America — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
28 ETFs hold DMRA
25 shown · $73.76M total exposure · 0.02% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.03% $25.1M $74.6B 2026-10-23
2 XBI State Street® SPDR® S&P® Biotech ETF SPDR (State Street) 0.16% $16.2M $10.4B 2026-10-23
3 VXF Vanguard Extended Market ETF Vanguard 0.01% $11.9M — 2026-09-30
4 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.05% $6.4M $13.7B 2026-10-23
5 VTWO Vanguard Russell 2000 ETF Vanguard 0.03% $5.8M — 2026-09-30
6 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.02% $2.9M $13.9B 2026-10-23
7 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.00% $1.5M $96.5B 2026-10-23
8 VFMO Vanguard U.S. Momentum Factor ETF Vanguard 0.05% $1.0M — 2026-10-23
9 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.05% $753,482 — 2026-09-30
10 RSSL Global X Russell 2000 ETF Global X 0.03% $484,494 — 2026-10-26
11 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.00% $352,393 $10.7B 2026-10-23
12 IWV iShares Russell 3000 ETF iShares (BlackRock) 0.00% $303,738 $20.4B 2026-10-23
13 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.02% $288,195 — 2026-09-30
14 FHLC Fidelity MSCI Health Care Index ETF Fidelity 0.01% $279,400 $3.8B 2026-10-23
15 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $87,737 — 2026-09-30
16 OMFS Invesco Russell 2000 Dynamic Multifactor ETF Invesco 0.02% $57,955 — 2026-10-24
17 ITWO ProShares Russell 2000 High Income ETF ProShares 0.03% $57,423 — 2026-10-26
18 WSML iShares MSCI World Small-Cap ETF iShares (BlackRock) 0.01% $54,539 $657.8M 2026-10-23
19 TMED T. Rowe Price Health Care ETF Nport 0.20% $46,506 — 2026-06-30
20 URTY ProShares UltraPro Russell2000 ProShares 0.02% $44,029 — 2026-10-26
21 RFLR Innovator U.S. Small Cap Managed Floor ETF Innovator 0.04% $37,035 $95.0M 2026-10-26
22 UWM ProShares Ultra Russell2000 ProShares 0.01% $30,891 — 2026-10-26
23 MSML iShares MSCI USA Small-Cap ETF iShares (BlackRock) 0.01% $23,494 $273.4M 2026-10-23
24 WCEO Hypatia Women CEO ETF Nport 0.17% $17,046 — 2026-07-31
25 KBFR Innovator U.S. Small Cap Managed 10 Buffer ETF Innovator 0.04% $5,166 $13.3M 2026-10-26
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.